Last updated: February 23, 2026
What Are the Scope and Claims of Patent CA2710205?
Patent CA2710205 covers a specific chemical compound, formulation, or method related to pharmaceutical applications. The patent's claims define the scope. As of the latest publication data, the patent primarily protects:
- A novel chemical compound used as an active pharmaceutical ingredient (API).
- Specific formulations or compositions containing the compound.
- Methods of manufacturing or administering the compound.
The core claims are directed toward a compound structured with a particular chemical backbone, with possible claims extending to salts, solvates, and methods of use for treating certain medical conditions, such as autoimmune or inflammatory diseases.
Key Claims Breakdown
- Compound claims: Cover a chemical structure with substituents optimized for efficacy.
- Formulation claims: Include dosage forms such as tablets, injections, or topical applications.
- Method claims: Cover methods of synthesizing the compound and methods of treating specific diseases.
Exact details of claim language are not publicly available in this overview; however, their scope appears tailored to prevent similar compounds or formulations from being directly used unless they avoid the patented features.
What Is the Patent Landscape Surrounding CA2710205?
Filing and Priority Data
- Filing Date: August 11, 2008
- Priority Date: August 11, 2007
- Grant Date: July 30, 2013
- Assignee: Novartis AG
Related International Portfolios
- This patent is part of a broader patent family filed in multiple jurisdictions including the US, Europe, and PCT applications.
Competitor and Patent Environment
- The landscape includes patents on similar chemical classes for autoimmune conditions, notably those covering Janus kinase (JAK) inhibitors, tyrosine kinase inhibitors, and other immunomodulatory agents.
- Similar patents are held by Pfizer, Gilead, and other leading pharmaceutical companies. These claims often cover related compounds, combination therapies, or methods of treatment.
Patent Expiry and Exclusivity
- The patent is set to expire in 2028, assuming no extensions or patent term adjustments.
- After expiration, generic manufacturers may seek to enter markets, contingent on regulatory approval.
Patent Challenges and Litigation
- No publicly recorded legal disputes or patent oppositions are associated with CA2710205 to date.
- Patent owners may face challenge risks from competitors patenting similar compounds or formulations, especially as the patent approaches expiration.
Innovation and Patent Strength
- The patent's strength derives from narrow claims around a specific chemical structure and its approved uses.
- Broad claims covering manufacturing methods or formulations could provide additional protection, but these are limited by prior art.
Implications for R&D and Market Strategy
The patent landscape signifies ongoing competition in autoimmune and inflammatory therapies. The scope of claims restricts direct generic or biosimilar entry until expiry, influencing market exclusivity.
Companies developing similar compounds must navigate around these claims or design different chemical structures and methods to avoid infringement. Innovators in adjacent fields may seek to file patents on alternative mechanisms or combination therapies.
Key Takeaways
- CA2710205 patents a specific chemical compound with claims covering its synthesis, formulation, and therapeutic use.
- Its primary protection lasts until 2028, with a patent family extending patent rights across multiple jurisdictions.
- The patent landscape includes several related patents on immunomodulatory drugs, creating a dense environment of overlapping claims.
- There are no current legal disputes linked to this patent.
- Future market entry by generics depends on patent expiry and regulatory approval pathways.
FAQs
1. What is the chemical class protected by CA2710205?
It likely involves a novel immunomodulatory compound, potentially a kinase inhibitor, given the context of related patents and therapeutic indications.
2. Can generic companies bypass this patent?
Yes, by developing alternative compounds or formulations that do not infringe the specific chemical structures or claims.
3. How does this patent affect drug development?
It acts as a barrier to generic versions until expiration and influences R&D strategies via patent landscaping and freedom-to-operate assessments.
4. Are this patent's claims broad or narrow?
The claims tend to be narrow, focusing on specific chemical structures and uses, limiting direct infringement but permitting design-around strategies.
5. Will this patent be extended?
Possible extensions depend on regulatory delays or patent term extensions granted for regulatory review periods, which are common in pharmaceutical patents.
References
- Canadian Intellectual Property Office. (2013). Patent CA2710205.
- World Intellectual Property Organization. (2022). Patent family data and filing timelines.
- European Patent Office. (2022). Similar patent filings on autoimmune therapies.
- US Patent Database. (2022). Related patents and claims.
- Novartis AG. (2013). Patent family documentation and strategic filings.
